Suzuki Keisuke, Suzuki Shiho, Ishii Yuko, Okamura Madoka, Matsubara Takeo, Fujita Hiroaki, Nozawa Narihiro, Kobayashi Saro, Hirata Koichi
Department of Neurology, Dokkyo Medical University, Japan.
Department of Neurology, Dokkyo Medical University, Japan.
J Neurol Sci. 2020 Apr 15;411:116692. doi: 10.1016/j.jns.2020.116692. Epub 2020 Jan 18.
Prostaglandin D2 (PGD2) induces sleep and may play a role in sleep and neurological disorders. We investigated PGD synthase (PGDS) levels in various sleep and neurological disorders.
Sixty-three patients with neurological or sleep disorders (Parkinson's disease with excessive daytime sleepiness (PDS), n = 19; PD without sleepiness (PDWS), n = 14; Alzheimer's disease (AD), n = 10; narcolepsy (NA), n = 10; sleep apnea syndrome (SAS), n = 10) and 21 healthy controls were included in this study. Plasma lipocalin-type PGDS (L-PGDS) and glutathione-dependent hematopoietic PGDS (H-PGDS) levels were assessed using an enzyme-linked immunosorbent assay.
H-PGDS levels were not significantly different among the groups. Compared with healthy controls, the PDWS, PDS and AD groups had higher levels of L-PGDS. Neither H-PGDS nor L-PGDS levels correlated with scores on the Epworth Sleepiness Scale or Pittsburgh Sleep Quality Index in any group.
We found higher levels of L-PGDS in patients with neurodegenerative diseases such as PD and AD. Whether increased L-PGDS levels reflect underlying sleepiness or the pathophysiology of neurodegenerative diseases needs further study.
前列腺素D2（PGD2）可诱导睡眠，并可能在睡眠和神经疾病中起作用。我们研究了各种睡眠和神经疾病中PGD合酶（PGDS）的水平。
本研究纳入了63例患有神经或睡眠障碍的患者（伴有日间过度嗜睡的帕金森病（PDS），n = 19；无嗜睡的帕金森病（PDWS），n = 14；阿尔茨海默病（AD），n = 10；发作性睡病（NA），n = 10；睡眠呼吸暂停综合征（SAS），n = 10）以及21名健康对照者。采用酶联免疫吸附测定法评估血浆脂质运载蛋白型PGDS（L-PGDS）和谷胱甘肽依赖性造血PGDS（H-PGDS）水平。
各组间H-PGDS水平无显著差异。与健康对照者相比，PDWS、PDS和AD组的L-PGDS水平较高。在任何组中，H-PGDS和L-PGDS水平均与爱泼沃斯嗜睡量表或匹兹堡睡眠质量指数评分无关。
我们发现帕金森病和阿尔茨海默病等神经退行性疾病患者的L-PGDS水平较高。L-PGDS水平升高是否反映潜在的嗜睡或神经退行性疾病的病理生理学需要进一步研究。
